ARDX — Ardelyx Inc
NASDAQ · Healthcare · Biotechnology
$3.76
+$0.00 (+0.00%)
Ardelyx Inc (ARDX) is a biotechnology company listed on NASDAQ. It is led by Michael G. Raab, based in 400 Fifth Avenue, Waltham, MA, United States, 02451, with about 489 employees. Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Latest reported ARDX revenue for 2025-09-30 was $110.3M. Net income was -$969.0K. Revenue was up 13.0% from 2025-06-30 to 2025-09-30. ARDX currently screens at market cap $1.37B.
Use this ARDX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ARDX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ARDX SEC filings page. Lician reads the product cache first so this HTML stays unique to Ardelyx Inc even when a live quote feed is slow.
About Ardelyx Inc
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
ARDX Key Statistics
Market Cap
$1.37B
Volume
736,292
Previous Close
$3.74
Day Range
$3.75 – $3.92
EPS
-$0.17
Revenue
$333.62M
Net Income
-$39.14M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+168.1%
Profit Margin
-11.7%
Employees
489
ARDX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $333.62M | $124.46M | $52.16M | $10.10M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$39.14M | -$66.07M | -$67.21M | -$158.16M |
| EPS (Diluted) | -$0.17 | -$0.30 | -$0.42 | -$1.52 |
Total Assets
$435.75M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$64.93M
Operating Cash Flow
-$44.81M
Free Cash Flow
$0.00
Ardelyx Inc Company Information
- President, CEO & Director
- Michael G. Raab
- Headquarters
- 400 Fifth Avenue, Waltham, MA, United States, 02451
- Website
- www.ardelyx.com
- Phone
- 510 745 1700
- IPO / Founded
- 2014-06-19
- Sector
- Healthcare
- Industry
- Biotechnology